Here are the DEF 14A proxy statements from Clover Health Investments, Corp (CLOV) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CLOV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLOV filings page.
Clover Health Investments, Corp. is holding its 2026 annual stockholder meeting on June 10, 2026 at 11:00 a.m. Eastern Time as a virtual-only event. Holders of Class A and Class B common stock at the April 15, 2026 record date may attend online, vote and submit questions.
Stockholders will vote on electing three Class II directors to serve until the 2029 meeting, a non-binding advisory "Say-on-Pay" proposal on 2025 executive compensation, and ratification of Ernst & Young LLP as independent auditor for 2026. The Board recommends voting "FOR" all three items.
The proxy describes Clover’s classified, seven-member Board with a separate Executive Chairperson, CEO and lead independent director, outlines committee structures and director independence, and details a pay‑for‑performance executive compensation program that emphasizes variable incentive pay, equity awards and long-term value alignment.